Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity.
作者： E. FENOUILLET , N. BLANES , A. BENJOUAD , J. C. GLUCKMAN
DOI: 10.1111/J.1365-2249.1995.TB05567.X
关键词:
摘要: During HIV-1 infection, the current tenet is that only anti-gag antibodies decline, while those directed at env remain stable. Among latter antibodies, to V3 domain of gp120 are assumed play a role in immune surveillance against HIV-1. We investigated correlation between anti-V3 antibody levels and clinical stage infection ability neutralize syncytium formation. Using V3-specific antigen-limited ELISA, we analysed panel 93 HIV-1+ sera peptides derived from different strains North American/European consensus sequence V3(Cs). Sera preferentially recognized representative V3(MN) strain Antibody reactivity or V3(Cs) actually declined relation with progression AIDS, whole recombinant gp160 gp41 immunodominant epitope remained There was strong (P < 0.0001) (Cs)/V3(MN) serum titres neutralized HIV-1MN-mediated syncytia. Serology based on ELISA indicates may decline during course HIV infection.
sci-hub.se 参考文章(34)
S Norley, R Kurth, T Vogel, The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. Journal of Immunology. ,vol. 153, pp. 1895- 1904 ,(1994)
M.P. Kieny, R. Lathe, Y. Rlvlère, K. Dott, D. Schmitt, M. Girard, L. Montagnler, J.-P. Lecocq, Improved antigenicity of the HIV env protein by cleavage site removal Protein Engineering. ,vol. 2, pp. 219- 225 ,(1988) , 10.1093/PROTEIN/2.4.317
K. Kobayashi, A. Takeda, S. Green, C. U. Tuazon, F. A. Ennis, Direct detection of infectious human immunodeficiency virus type 1 (HIV-1) immune complexes in the sera of HIV-1-infected persons The Journal of Infectious Diseases. ,vol. 168, pp. 729- 732 ,(1993) , 10.1093/INFDIS/168.3.729
T.J. Brenner, K.E. Dahl, G. Miller, W.A. Andiman, W.A. Andiman, B. Olson, G. Miller, W.A. Andiman, G. Miller, Relation between HIV-1 syncytium inhibition antibodies and clinical outcome in children. The Lancet. ,vol. 337, pp. 1001- 1005 ,(1991) , 10.1016/0140-6736(91)92660-T
M. T. Wong, R. Q. Warren, S. A. Anderson, M. J. Dolan, C. W. Hendrix, S. P. Blatt, G. P. Melcher, R. N. Boswell, R. C. Kennedy, Longitudinal Analysis of the Humoral Immune Response to Human Immunodeficiency Virus Type 1 (HIV-1) gp160 Epitopes in Rapidly Progressing and Nonprogressing HIV-1-Infected Subjects The Journal of Infectious Diseases. ,vol. 168, pp. 1523- 1527 ,(1993) , 10.1093/INFDIS/168.6.1523
A. Rubinstein, T. A. Calvelli, D. G. Wood, Y. Devash, K. J. Reagan, Erratum: Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain (Proc. Natl. Acad. Sci. USA (May 1990) 87 (3445-3449)) Proceedings of the National Academy of Sciences of the United States of America. ,vol. 88, ,(1991)
J P Moore, D D Ho, Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. Journal of Virology. ,vol. 67, pp. 863- 875 ,(1993) , 10.1128/JVI.67.2.863-875.1993
L Milich, B Margolin, R Swanstrom, V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. Journal of Virology. ,vol. 67, pp. 5623- 5634 ,(1993) , 10.1128/JVI.67.9.5623-5634.1993
M Schreiber, H Petersen, C Wachsmuth, H Müller, F T Hufert, H Schmitz, Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum Journal of Virology. ,vol. 68, pp. 3908- 3916 ,(1994) , 10.1128/JVI.68.6.3908-3916.1994
R Q Warren, S A Anderson, W M Nkya, J F Shao, C W Hendrix, G P Melcher, R R Redfield, R C Kennedy, Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity. Journal of Virology. ,vol. 66, pp. 5210- 5215 ,(1992) , 10.1128/JVI.66.9.5210-5215.1992